Last reviewed 2026-04-23 · How we verify

Alkalinized Lidocaine-Heparin

Lidocaine inhibits sodium channels, while heparin inhibits coagulation.

Lidocaine inhibits sodium channels, while heparin inhibits coagulation. Used for Cardioversion, defibrillation, and local anesthesia.

At a glance

Mechanism of action

Lidocaine is a local anesthetic that blocks sodium channels, preventing the initiation and transmission of nerve impulses. Heparin is an anticoagulant that inhibits thrombin and factor Xa, preventing blood clot formation.

Approved indications

• Cardioversion, defibrillation, and local anesthesia

Common side effects

• Nausea
• Vomiting
• Hypotension

Key clinical trials

• Safety, Efficacy, and Frequency of Administration of VNX001 in the Treatment of Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS) (PHASE2)
• Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPS (PHASE2)
• The Female Microbiome in Patients Undergoing Bladder Instillation Therapy (PHASE2)
• Bladder Instillations Versus Onabotulinumtoxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome (PHASE2)
• Study of U101 for Bladder Pain and/or Urgency (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Alkalinized Lidocaine-Heparin CI brief — competitive landscape report
• Alkalinized Lidocaine-Heparin updates RSS · CI watch RSS
• Urigen portfolio CI